J Korean Diabetes > Volume 15(3); 2014 > Article
The Journal of Korean Diabetes 2014;15(3):151-157.
DOI: https://doi.org/10.4093/jkd.2014.15.3.151    Published online September 30, 2014.
SGLT2 억제제의 혈당조절과 무관한 작용
The Non-glycemic Effects of SGLT2 Inhibitor.
Dae Ho Lee
Department of Internal Medicine, Wonkwang University School of Medicine & Hospital, Iksan, Korea. drhormone@naver.com
Sodium glucose cotransporter 2 (SGLT2) inhibitors have recently been introduced as a new class of anti-diabetic agents. In addition to their glycemic action, SGLT2 inhibitors also have a number of non-glycemic effects that may contribute to renal and/or cardiovascular benefits. These include effects on tubuloglomerular feedback in the kidney, body weight, blood pressure, and serum uric acid. Other non-glycemic effects of SGLT2 inhibitors that need to be further studied include the effects on lipid profiles, food intake, and secretion of hormones such as leptin, incretins, and aldosterone. Also, the exact mechanisms of various non-glycemic actions should be further studied. Additionally, SGLT2 inhibitor therapy in combination with other drugs may have beneficial glycemic and non-glycemic effects.
Key Words: Diabetes mellitus, Sodium glucose cotransporter 2, Antidiabetic agent

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer